Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes.
暂无分享，去创建一个
J. Esteve | L. Arenillas | F. Solé | J. Sierra | L. Zamora | Laura Palomo | C. Motlló | O. Salamero | D. Gallardo | X. Ortín | I. Granada | Francisco Fuster-Tormo | M. Arnán | S. Vives | M. Cervera | M. Hoyos | M. Pratcorona | P. Acha | J. Montoro | Antonio G. García | Marta Canet | E. Ortega | J. Baragay | Antonio G. García | F. Fuster-Tormo | L. Palomo
[1] Johannes G. Reiter,et al. Single-cell mutational profiling enhances the clinical evaluation of AML MRD. , 2020, Blood advances.
[2] J. Cigudosa,et al. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2019, British journal of haematology.
[3] R. Collins,et al. Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.
[4] T. LaFramboise,et al. Consequences of mutant TET2 on clonality and subclonal hierarchy , 2018, Leukemia.
[5] Anthony Stein,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[6] Steven M. Chan,et al. Isocitrate dehydrogenase mutations in myeloid malignancies , 2016, Leukemia.
[7] F. Solé,et al. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features , 2016, Oncotarget.
[8] M. Konopleva,et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML , 2015, American journal of hematology.
[9] Manuela Zucknick,et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.